Synaptogenix (NASDAQ:TAOX) Releases Earnings Results

Synaptogenix (NASDAQ:TAOX) posted its quarterly earnings data on Thursday. The company reported ($1.83) EPS for the quarter, Zacks reports.

Synaptogenix Price Performance

Shares of NASDAQ TAOX remained flat at $3.48 during midday trading on Thursday. The stock had a trading volume of 103,311 shares, compared to its average volume of 146,936. Synaptogenix has a fifty-two week low of $3.18 and a fifty-two week high of $10.00. The company has a market cap of $26.00 million, a P/E ratio of -0.26 and a beta of 1.45. The business has a fifty day moving average of $3.63 and a two-hundred day moving average of $4.42.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a report on Friday, July 17th. Wall Street Zen raised shares of Synaptogenix from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Synaptogenix has an average rating of “Sell”.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.